Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$4.14
-1.1%
$4.61
$3.21
$8.06
$989.32M0.764.45 million shs1.05 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$29.71
-0.8%
$28.15
$23.23
$42.29
$956.22M0.63427,313 shs17,174 shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$1.14
-3.8%
$1.04
$0.50
$1.55
$260.17M1.821.53 million shs641,796 shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$23.87
-0.9%
$20.19
$16.16
$26.55
$968.97M0.62197,322 shs20,501 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+2.96%+23.30%-13.28%-34.28%-47.29%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+0.44%+0.54%+10.92%+0.17%-12.27%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
+8.26%+8.26%+40.48%-16.90%+72.69%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
-0.17%-2.07%+39.33%-0.33%+32.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.5525 of 5 stars
4.52.00.04.42.72.50.6
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.1278 of 5 stars
3.40.00.03.04.10.82.5
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.8347 of 5 stars
3.52.00.04.72.61.70.0
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
3.5513 of 5 stars
0.83.02.51.12.93.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ardelyx, Inc. stock logo
ARDX
Ardelyx
2.90
Moderate Buy$10.39151.24% Upside
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.80
Moderate Buy$43.8047.43% Upside
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.00
Buy$7.75582.82% Upside
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.50
Reduce$20.00-16.20% Downside

Current Analyst Ratings Breakdown

Latest GOSS, PAHC, ARDX, and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.00
5/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00
5/8/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$11.00
4/17/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
4/15/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$20.00
4/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
3/24/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
3/18/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$361.71M2.74N/AN/A$0.73 per share5.66
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$664.28M1.44$10.76 per share2.76$5.99 per share4.96
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$114.70M2.25N/AN/A$0.28 per share4.05
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$1.19B0.81$2.20 per share10.87$6.09 per share3.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.22N/A13.34N/A-11.73%-24.87%-10.51%8/7/2025 (Estimated)
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$48.15M$1.2212.834.94N/A14.78%104.67%18.38%N/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$179.82M-$0.23N/AN/AN/AN/A-127.28%-22.12%N/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$2.42M$0.7849.8011.360.451.75%25.35%6.21%N/A

Latest GOSS, PAHC, ARDX, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50$1.49-$0.01$0.07$174.96 million$177.76 million
5/7/2025Q3 2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/1/2025Q1 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million
3/18/2025Q4 2024
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.15-$0.15N/A-$0.15$7.02 million$9.38 million
2/27/2025Q4 2024
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.54$1.63+$0.09$0.36$179.68 million$181.95 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.482.01%N/A61.54%N/A

Latest GOSS, PAHC, ARDX, and COLL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ardelyx, Inc. stock logo
ARDX
Ardelyx
0.87
4.58
4.31
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.43
0.97
0.88
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.64
6.74
6.74
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.99
3.20
1.37

Institutional Ownership

CompanyInstitutional Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%

Insider Ownership

CompanyInsider Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.51%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
50.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90239.26 million222.88 millionOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million30.97 millionOptionable
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
180227.22 million215.27 millionOptionable
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,86040.53 million20.22 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$4.14 -0.05 (-1.08%)
As of 11:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$29.71 -0.25 (-0.83%)
As of 11:28 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Gossamer Bio stock logo

Gossamer Bio NASDAQ:GOSS

$1.14 -0.05 (-3.81%)
As of 11:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$23.86 -0.23 (-0.93%)
As of 11:28 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.